1,237 reports of this reaction
5.2% of all GANCICLOVIR SODIUM reports
#3 most reported adverse reaction
CYTOMEGALOVIRUS INFECTION is the #3 most commonly reported adverse reaction for GANCICLOVIR SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 1,237 FDA adverse event reports linking GANCICLOVIR SODIUM to CYTOMEGALOVIRUS INFECTION. This represents approximately 5.2% of all 23,974 adverse event reports for this drug.
Patients taking GANCICLOVIR SODIUM who experience cytomegalovirus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS INFECTION is moderately reported among GANCICLOVIR SODIUM users, representing a notable but not dominant share of adverse events.
In addition to cytomegalovirus infection, the following adverse reactions have been reported for GANCICLOVIR SODIUM:
The following drugs have also been linked to cytomegalovirus infection in FDA adverse event reports:
CYTOMEGALOVIRUS INFECTION has been reported as an adverse event in 1,237 FDA reports for GANCICLOVIR SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS INFECTION accounts for approximately 5.2% of all adverse event reports for GANCICLOVIR SODIUM, making it one of the most commonly reported side effect.
If you experience cytomegalovirus infection while taking GANCICLOVIR SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.